Cerus Corporation to Release Third Quarter 2022 Financial Results on November 3, 2022

Rhea-AI Summary

Cerus Corporation (NASDAQ: CERS) will release its third quarter 2022 financial results on November 3, 2022, after market close. A conference call and webcast will be held at 4:30 P.M. ET that day, where management will discuss financials and business outlook. The event can be accessed via the Cerus Investor Relations page. A replay will be available approximately three hours post-call until November 17, 2022. The company focuses on safeguarding the blood supply with its INTERCEPT Blood System, which is FDA approved for platelets and plasma.

Positive

• Cerus has FDA approval for the INTERCEPT Blood System for platelets and plasma.
• The INTERCEPT red blood cell system is under regulatory review in Europe and in late-stage clinical development in the US.
• The INTERCEPT Blood System for Cryoprecipitation is approved for producing INTERCEPT Fibrinogen Complex.

Negative

• None.

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2022 financial results will be released on Thursday, November 3, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event.

A replay will be available on Cerus’ website and will be available approximately three hours after the call through November 17, 2022.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221020005165/en/

Jessica Hanover – Vice President, Corporate Affairs

Cerus Corporation

925-288-6137

Source: Cerus Corporation

FAQ

When will Cerus Corporation release its Q3 2022 financial results?

Cerus Corporation will release its Q3 2022 financial results on November 3, 2022, after market close.

What time is the Cerus Corporation conference call for Q3 2022 results?

The conference call for Cerus Corporation's Q3 2022 results will take place at 4:30 P.M. ET on November 3, 2022.

How can I access the Cerus conference call for financial results?

You can access the Cerus conference call via the Investor Relations page on their website at ir.cerus.com.

Is there a replay available for the Cerus conference call?

Yes, a replay of the Cerus conference call will be available approximately three hours after the call and accessible until November 17, 2022.